Ibn Sina Pharmaceutical Industry has declared a 63% cash dividend for the financial year ending June 30, marking its highest payout in seven years. The announcement follows a 10% increase in net profit, which reached Tk 67.04 crore, up from Tk 60.55 crore the previous year.
The company’s consolidated earnings per share (EPS) also rose, increasing to Tk 21.46 compared to Tk 19.38 in the previous fiscal year, as disclosed on the Dhaka Stock Exchange (DSE).
Additionally, Ibn Sina’s consolidated net asset value per share was reported at Tk 111.94 for 2023-24, while its net operating cash flow per share stood at Tk 12.48.
Founded in 1983, Ibn Sina has established itself as a significant player in the local pharmaceutical market, offering diverse products, including herbal and Unani medicines. However, despite the strong financial results and attractive dividend announcement, the company’s shares experienced a decline, dropping by 4.99% to Tk 329.40 on the DSE following the news.
